The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study
Open accessAbstract
Purpose: The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival. Patients and Methods: Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR). Results: Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P < .00005), but not for ductal carcinoma in situ. Results in the BRCA1 group were worse compared to the BRCA2, the high-, and the moderate-risk groups, respectively, for mammography sensitivity (25.0% v 61.5%, 45.5%, 46.7%), tumor size at diagnosis ≤ 1 cm (21.4% v 61.5%, 40.9%, 63.6%), proportion of DCIS (6.5% v 18.8%, 14.8%, 31.3%) and interval cancers (32.3% v 6.3%, 3.7%, 6.3%), and age at diagnosis younger than 30 years (9.7% v 0%). Cumulative distant metastasis-free and overall survival at 6 years in all 42 BRCA1/2 mutation carriers with invasive breast cancer were 83.9% (95% CI, 64.1% to 93.3%) and 92.7% (95% CI, 79.0% to 97.6%), respectively, and 100% in the familial groups (n = 43). Conclusion: Screening results were somewhat worse in BRCA1 mutation carriers, but 6-year survival was high in all risk groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973 · cited 1×
“The risk of breast cancer can be reduced by prophylactic surgery or chemoprevention.(5-9) A promising strategy to reduce the risk of breast cancer death is early diagnosis by intensive surveillance.”
BackgroundSelf-citationRebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Self-citationBrekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233
Self-citation
Cited by
Early Detection of Cancer: Past, Present, and Future
Schiffman, J. D., Fisher, P. G., & Gibbs, P. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.57 · Cited by 327
Riedl, C. C., Luft, N., Bernhart, C., Weber, M., Bernathova, M., Tea, M.-K. M., Rudas, M., Singer, C. F., & Helbich, T. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.8626 · Cited by 300
Li-Fraumeni syndrome: cancer risk assessment and clinical management
McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 281
Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)
Saadatmand, S., Obdeijn, I., Rutgers, E. J., Oosterwijk, J. C., Tollenaar, R. A., Woldringh, G. H., Bergers, E., Verhoef, C., Heijnsdijk, E. A., Hooning, M. J., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29534 · Cited by 96
Self-citationVencken, P. M. L. H., Kriege, M., Hooning, M., Menke‐Pluymers, M. B., Heemskerk‐Gerritsen, B. A. M., van Doorn, L. C., Collée, M. M., Jager, A., van Montfort, C., Burger, C. W., et al. (2013) · Cancer · doi:10.1002/cncr.27839 · Cited by 40
Self-citation
Metadata
- Authors
- Rijnsburger, A. J., Obdeijn, I.-M., Kaas, R., Tilanus-Linthorst, M. M. A., Boetes, C., Loo, C. E., Wasser, M. N. J. M., Bergers, E., Kok, T., Muller, S. H., Peterse, H., Tollenaar, R. A. E. M., Hoogerbrugge, N., Meijer, S., Bartels, C. C. M., Seynaeve, C., Hooning, M. J., Kriege, M., Schmitz, P. I. M., Oosterwijk, J. C., de Koning, H. J., Rutgers, E. J. T., & Klijn, J. G. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-12-20
- Volume
- 28
- Issue
- 36
- Pages
- 5265-5273
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2172296348
- Cited by
- 183
- References
- 5
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. https://app.cochat.ai/papers/10.1200/jco.2009.27.2294
- The paper
- Rijnsburger, A. J., Obdeijn, I.-M., Kaas, R., Tilanus-Linthorst, M. M. A., Boetes, C., Loo, C. E., Wasser, M. N. J. M., Bergers, E., Kok, T., Muller, S. H., Peterse, H., Tollenaar, R. A. E. M., Hoogerbrugge, N., Meijer, S., Bartels, C. C. M., Seynaeve, C., Hooning, M. J., Kriege, M., Schmitz, P. I. M., . . . Klijn, J. G. M. (2010). BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.27.2294
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.